May 15, 2026
BioXcel Therapeutics Provides Business Update and Reports First Quarter 2026 Financial ResultsVIEW RELEASE
Apr 17, 2026
BioXcel Therapeutics Announces Virtual Event to Discuss Commercial Launch Plan Based on Market Opportunity Assessment for IGALMI® in the At-Home SettingVIEW RELEASE
Apr 08, 2026
BioXcel Therapeutics Announces Enrollment of First Patients in U.S. Department of War-Funded Study of BXCL501 (Sublingual Dexmedetomidine) for Treatment of Acute Stress ReactionsVIEW RELEASE
Stock Information
BioXcel Therapeutics, Inc.
May 15, 2026 04:00 PM
MARKET/SYMBOL
Nasdaq:
BTAI
PRICE
1.14
CHANGE
-0.07 (-5.79%)
